相关实验视频

Updated: Jan 12, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

瑞抑制炎症Th17极化,以减轻阿尔茨海默氏症疾病的发病因子

Yufei Li^1,2, Ao Sun^1,2, Jingjing Han^1,3

¹Department of Basic Medical Science, Jiangsu Medical College, Yancheng, Jiangsu, China.

CNS neuroscience & therapeutics

|November 5, 2025

概括

瑞是一种天然的黄类化合物,通过抑制RORγt和减少神经炎症,显示出对阿尔茨海默病 (AD) 的治疗潜力. 这种治疗改善了小鼠的认知功能,并减少了老年痴呆症的关键病理.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默病 (AD) 的特点是神经炎症.
Th17细胞及其转录因子RORγt在AD病变发生过程中发挥作用.
向RORγt介导的神经炎症为AD提供了一个潜在的治疗策略.

研究的目的:

为了研究瑞的治疗潜力,天然的黄类,对于阿尔茨海默病.
为了确定myricetin是否可以抑制RORγt和调节Th17细胞介导的神经炎症.
在AD模型中阐明myricetin作用背后的机制.

主要方法:

虚拟查发现myricetin是RORγt抑制剂,通过分子对接证实了这一点.
在体内研究中,对3xTg-AD小鼠进行了myricetin治疗,随后进行了行为和病理评估.
在体外测试中检查了myricetin对Th17偏振和RORγt-IL-17信号传递的影响.

主要成果:

瑞有效地抑制了RORγt,并抑制了Th17极化和IL-17的产生.
用myricetin治疗改善了AD小鼠的认知功能.
在AD小鼠中,myricetin减少了Aβ斑块,化陶,神经元损伤和微质激活.

结论:

瑞通过抑制RORγt驱动的Th17极化来改善阿尔茨海默病的病理学.
瑞显示出作为阿尔茨海默病治疗新型药物的显著治疗潜力.
针对RORγt-IL-17轴为AD干预提供了一个有希望的途径.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.罗尔特的时间.Th17 这是一个很好的方法.这种药物是myricetin.虚拟选虚拟选虚拟选

更多相关视频

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...